1. The addition of ramucirumab to irinotecan in patients with ramucirumab-refractory advanced or recurrent gastric or gastroesophageal cancer (AGC) did ...
1. Event-free survival at 24 months was 67.4% in the durvalumab group and 58.5% in the placebo group, with HR ...
1. In this retrospective cohort study, age-specific incidence rates of appendiceal adenocarcinoma increased by time period. 2. Local drift for ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Use of the semi-blunt dissection technique with endoscopic resection of gastric submucosal tumours was associated with a smaller maximum ...
Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of grade 3 or higher ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click here to read this study in Nature Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the ...
